Eli Lilly Trades Below $890 Resistance Despite Mounjaro Demand
Eli Lilly shares trade at a steep discount after falling back from April 2025’s $890 resistance, presenting potential value versus peers. Strong uptake of its GLP-1 obesity drug Mounjaro fuels calls to redefine obesity, while most-favored-nation pricing deals could limit U.S. margins.
1. Valuation and Recent Selloff
After encountering resistance at $890 in April 2025, Eli Lilly shares have declined significantly, driving its forward price-earnings multiple to multi-year lows. This retreat has attracted value investors evaluating the stock against historical averages and healthcare sector benchmarks.
2. Mounjaro’s Impact on Obesity Market
Eli Lilly’s GLP-1 obesity therapy Mounjaro has seen robust demand, with prescription volumes rising sharply as physicians and patients seek new weight-loss options. The surge has prompted medical organizations to reconsider the clinical definition of obesity, potentially expanding the addressable patient population.
3. Potential Pricing Constraints
Most-favored-nation pricing initiatives, designed to align U.S. drug costs with lower prices abroad, could cap Lilly’s list prices and narrow margins. Similar drugs have traded 67%–82% cheaper in the U.K., illustrating the potential earnings headwind if broader benchmarking deals are adopted.